



Wat is nanotechnologie en welke zijn de mogelijke gezondheidseffecten voor de werknemers

Peter Hoet
K.U.Leuven
Pneumology, Lung Toxicology
Peter.hoet@med.kuleuven.be



Wat is nanotechnologie en welke zijn de mogelijke gezondheidseffecten voor de werknemers

Peter Hoet
K.U.Leuven
Pneumology, Lung Toxicology
Peter.hoet@med.kuleuven.be



Overview

- Introduction:
 - Definition: Nanomaterials – ultrafine particles?
 - Use of nanomaterials
 - Safe Nanomaterials
- Issues in NanoToxicology?
 - Role of size (nano versus larger)
 - Surface
 - Systemic delivery
 - Role of shape
 - One material different shapes
 - CNT
- Conclusions



Overview

- **Introduction:**
 - Definition: Nanomaterials – ultrafine particles?
 - Use of nanomaterials
 - Safe Nanomaterials
- **Issues in NanoToxicology?**
 - Role of size (nano versus larger)
 - Surface
 - Systemic delivery
 - Role of shape
 - One material different shapes
 - CNT
- **Conclusions**



Definition?

- European Academy at Bad Neuenahr: “Nanotechnology (therefore man-made) is dealing with functional systems based on the use of subunits with **specific size dependent properties** of the individual sub-units or of a system of those.”
 - very general; **no exact size** $\neq 100\text{ nm}$
 - **excludes** non purpose made materials such as soot and dust.
- Nanoparticle: one dimension $<100\text{ nm}$ (and larger than 1 nm)
 - Spherical
 - Rods & Tubes
 - Surfaces




Do we “need” nanotechnology





Do we “need” nanomaterials




Materials

Light as plastic, strong as steel



Water

Clean water any time, any place



Medicine

*Smart drugs that kill the disease,
not the person*





Energy

*“PowerPlastic™ that converts light
to energy - anywhere”*



Definition?

- European Academy at Bad Neuenahr: “Nanotechnology (therefore man-made) is dealing with functional systems based on the use of subunits with specific size dependent properties of the individual sub-units or of a system of those.”
 - very general; no exact size \neq 100 nm
 - excludes non purpose made materials such as soot and dust.
- Nanomaterials: one dimension <100 nm (and larger than 1 nm)
 - Spherical
 - Rods & Tubes
 - Surfaces





≠ Nano materialS ≠ Nano particleS

Origin

- natural
- unintentionally released
- manufactured („old“, „new“)

Chem. composition

- metals/ metal oxides
- polymers, carbon
- semiconductors
- biomolecules
- compounds ...

Nano-capsules Ultrafine Aerosols
Nanoparticulate Materials
Quantum dots Nano-particles
 Nano-tubes

Dispersion in

- gases (aerosols)
- liquids (e.g. gels, ferrofluids)
- solids (e.g. matrix materials)

Shape/Structure

- spheres
- needles
- platelets
- tubes

Aggregation state


- single particles
- aggregates
- agglomerates

Surface modification

- untreated (as obtained in production process)
- coated (e.g. conjugates, polymeric films)
- core/shell particles (e.g. spheres, capsules)




Nanotechnology = fast evolving





USE: What is produced?


www.nanotechproject.org/inventories/consumer/analysis_draft/






USE: Main applications?

www.nanotechproject.org/inventories/consumer/analysis_draft/






Safe nanomaterials?



Risk assessment
Systematic scientific characterisation of
potential adverse health effects
resulting from human **exposure** to
hazardous agents (or situations).



Safe nanomaterials?



Does nano play a role in
Hazard?
Exposure?



Overview

- Introduction:
 - Definition: Nanomaterials – ultrafine particles?
 - Use of nanomaterials
 - Safe Nanomaterials
- Issues in NanoToxicology?
 - Role of size (nano versus larger)
 - Surface
 - Systemic delivery
 - Role of shape
 - One material different shapes
 - CNT
- Conclusions




Issues in NanoToxicology: SIZE

1 μM
= 0.000 001 m
= 0.001 mm
= 1 000 nm

diameter

0.1 μM = 100 nm
diameter

0.01 μM = 10 nm
diameter






Issues in NanoToxicology: SIZE

- Existing molecule e.g. TiO₂
 - Known in microsize (low toxicity)
 - Now in nanosize?

New risk assessment?

Yes – No?


Why yes – Why no?





Size plays a role!

Amorphous monodisperse silica: In press: Napierska et al Small 2008



Size, number and surface area

Mass = 10 µg

Density = 1 kg/dm³

Diameter (µm)	N° particles	Surface area (µm ²)
0.01	19 000 000 $\times 10^6$	6 000 $\times 10^6$
0.05	153 000 $\times 10^6$	1 200 $\times 10^6$
0.1	19 000 $\times 10^6$	600 $\times 10^6$
0.5	153 $\times 10^6$	120 $\times 10^6$
1.0	19 $\times 10^6$	60 $\times 10^6$




Issues in NanoToxicology: SIZE

- Existing molecule e.g. TiO₂
 - Known in microsize
 - Now in nanosize

New risk assessment?
Probably Yes


Why?

- Different (more) toxicity
 - Surface & reactivity!
- ?





Bioavailability: deposition in lung



Inhalation of particles
≠
deposition



Figure 6

Regional deposition of inhaled NP with diameters between 1 nm and 1000 nm for nose and for mouth breathing in the extrathoracic airways (ET), the bronchial airways (Bb) and the alveolar region (AI) during breathing at rest, as predicted by ICRP 66 model (ICRP, 1994).



Systemic uptake of nanomaterials after inhalation in humans

Inhalation of ^{99m}Tc -carbon particles (“Technegas”)



Nemmar et al.
Circulation 2002, 105, 411



Issues in NanoToxicology: SIZE

- Existing molecule e.g. TiO₂
 - Known in microsize
 - Now in nanosize

New risk assessment?


Probably Yes

Why?

- Different (more) toxicity
 - Surface?
- Systemic delivery
 - Higher/different internal exposure/dose



Issues in NanoToxicology: SHAPE



Nano-ZnO: One chemistry, many shapes

Courtesy of Prof. Z.L. Wang, Georgia Tech



SHAPE plays a role

- Delivery
 - Inhalation
 - Skin penetration
- Mechanical damage
 - Needle vs spheres
- Time of exposure
 - Excretion & Biopersistent



One study ...

Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study

CRAIG A. POLAND¹, RODGER DUFFIN¹, IAN KINLOCH², ANDREW MAYNARD³,
WILLIAM A. H. WALLACE¹, ANTHONY SEATON⁴, VICKI STONE⁵, SIMON BROWN¹,
WILLIAM MACNEE¹ AND KEN DONALDSON^{1*}


Nature Nanotechnology May 20 2008






Nature Nanotechnology May 2008

a

Inflammatory response
(24 h post-instillation)

**c**

Granuloma response
(7 days post-instillation)

**b****d**



Other study

TOXICOLOGICAL SCIENCES 110(2), 442–448 (2009)
doi:10.1093/toxsci/kfp100
Advance Access publication May 8, 2009

Absence of Carcinogenic Response to Multiwall Carbon Nanotubes in a 2-Year Bioassay in the Peritoneal Cavity of the Rat

Julie Muller,* Monique Delos,† Nadtha Panin,* Virginie Rabolli,* François Huaux,* and Dominique Lison*,¹

*Industrial Toxicology and Occupational Medicine Unit, Catholic University of Louvain, 1200 Brussels, Belgium; and †Laboratory of Pathology, University Hospital of Mont-Godinne, Catholic University of Louvain, 5530 Yvoir, Belgium

Received April 8, 2009; accepted April 30, 2009

- Crocidolite (positive controls) → expected carcinogenic response
- No clear evidence of a similar activity for MWCNT
- The negative response to MWCNT in the study → critically interpretation + and calls for further studies
 - Different nanotube preparations
 - Different dosing regimens
 - Other bioassays




Overview

- Introduction:
 - Definition: Nanomaterials – ultrafine particles?
 - Use of nanomaterials
 - Safe Nanomaterials
- Issues in NanoToxicology?
 - Role of size (nano versus larger)
 - Surface
 - Systemic delivery
 - Role of shape
 - One material different shapes
 - CNT
- Conclusions



Conclusion: Safe nanomaterials



Each chemical entity → more than one evaluation!

There is no universal “nanoparticle” to fit all the cases

Physico-chemical characteristics

Crystal structure, Size, aggregation, dissolution, ...

Exposure & delivery micro vs nano

+ (Correct) test conditions



Lung Toxicology (KULeuven)
Ben Nemery
Abderrahim Nemmar
Jorina Geys
Ernesto Alfaro-Moreno
Katrien Iuyts
Dorota Naprieska
Barbara Legiest

Centre Molecular
Vascular Biology (KULeuven)
Marc Hoylaerts

Pathology (KULeuven)
Eric Verbeken

Thank You For Your Attention